-- Hutchmed (China)'s (HKG:0013) new drug application for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia has been accepted for review and granted priority review by China's National Medical Products Administration.
Sovleplenib is being developed for the treatment of immune diseases and hematological malignancies, according to a Wednesday Hong Kong bourse filing.